847615-35-4

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 16532-79-9 4-Bromophenylacetonitrile 
• 846049-40-9 (1-benzyl-piperidin-4-ylidene)-(4-bromo-phenyl)-acetonitrile 

Downstream Products

• 847615-36-5 (1-benzyl-piperidin-4-yl)-(4-bromo-phenyl)-acetaldehyde 
• 847615-39-8 4-(1-benzyl-piperidin-4-yl)-4-(4-bromo-phenyl)-butyraldehyde 
• 847615-38-7 4-(1-benzyl-piperidin-4-yl)-4-(4-bromo-phenyl)-butyric acid methyl ester 
• 904283-18-7 4-(1-benzyl-piperidin-4-yl)-4-(3'-cyano-biphenyl-4-yl)-butyric acid methyl ester 
• 847615-42-3 2-[3-(1-benzyl-piperidin-4-yl)-3-(4-bromo-phenyl)-propyl]-5,7-dichloro-1H-benzoimidazole 
• 847615-42-3 2-[3-(1-benzyl-piperidin-4-yl)-3-(4-bromo-phenyl)-propyl]-4,6-dichloro-1H-benzoimidazole 
• 904283-02-9 4-(3'-cyano-biphenyl-4-yl)-N-(3,4-difluoro-phenyl)-4-piperidin-4-yl-butyramide 
• 904283-20-1 2-[3-(1-benzyl-piperidin-4-yl)-3-(4-bromo-phenyl)-propyl]-4-chloro-5-fluoro-1H-benzoimidazole 
• 904283-21-2 2-[3-(1-benzyl-piperidin-4-yl)-3-(4-bromo-phenyl)-propyl]-5-fluoro-6-trifluoromethyl-1H-benzoimidazole 
• 904283-01-8 4-(1-benzyl-piperidin-4-yl)-4-(3'-cyano-biphenyl-4-yl)-N-(3,4-difluoro-phenyl)-butyramide 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of piperidine-based melanin-concentrating hormone receptor 1 antagonists

Isosteric replacement of the urea group of lead compound 1 led to novel substituted piperidine phenylamide analogues. SAR on the electron-induced effects of various linkers as well as substituents on the phenyl rings and the piperidine nitrogen has been investigated. Many single-digit nanomolar MCH R1 antagonists have been identified from this series.

2-Substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

The present invention discloses compounds of formula I wherein Ar, Y, m, n, R1 and R4 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.